G1 Therapeutics has reported preliminary results from its ongoing Phase II clinical trial of trilaciclib for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
The single-arm study enrolled 30 subjects who received prior treatment with PD-(L)1 Inhibitor, sacituzumab govitecan-hziy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
People who received trilaciclib prior to sacituzumab showed 50% reductions in the incidence of adverse events such as neutropenia, anaemia, and diarrhoea.
In addition, patients with PD-L1(+) tumours who received trilaciclib responded earlier compared to patients with PD-L1(-) tumours.
The data also demonstrated that trilaciclib has a significant effect on longer-term endpoints such as overall survival compared to earlier efficacy measures of overall response rate and progression-free survival.
In addition to protecting the initial damage caused by ADC therapy, trilaciclib’s immune-mediated mechanism of action improved long-term immune surveillance by increasing certain memory T cells.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataG1 Therapeutics chief medical officer Raj Malik said: “It is too early to determine the efficacy of trilaciclib prior to sacituzumab in this patient population.
“Given that this trial includes a heavily pretreated patient population, we are enthusiastic about these data to date.
“We will continue to monitor efficacy to assess the potential of trilaciclib to improve overall survival – by protecting the immune system and stimulating long-term immune surveillance – when combined with additional treatment regimens beyond gemcitabine/carboplatin for patients with TNBC. We look forward to these overall survival data in the first quarter of 2024.”
